Blood thinning treatments, known as anticoagulants, reduce the blood’s ability to form clots. They are an important treatment, for instance in patients with an irregular heart beat (atrial fibrillation) who are at increased risk of stroke. However, in emergency situations when speed matters, such as rapid initiation of surgery for injuries after a traffic accident or in the case of a life-threatening bleed, then rapid reversal of anticoagulation may be required. A specific reversal agent that immediately stops the anticoagulant effect provides an important treatment option for patients and physicians. Boehringer Ingelheim has advanced anticoagulation care by developing the first specific reversal agent to a non-vitamin K antagonist oral anticoagulant (NOAC).